Carboplatin and cisplatin pharmacokinetics after intrapleural combination treatment in patients with malignant pleural effusion

Abstract

The pharmacologic results seem to exclude a pharmacokinetic interaction between CBDCA and DDP and suggest that a dose of CBDCA 2-fold higher than that used in this study associated intrapleurally with 60 mg/m2 DDP could induce an acceptable and predictable myelosuppression.

Intrapleural administration of lipoplatin in an animal model

“…This route of administration might consequently increase the treatment efficacy while decreasing toxicity [17]. Several drugs have been used intrapleurally such as platinum compounds [18,19], etoposide [20], paclitaxel [21] and pemetrexed [22]. We hypothesized that, compared with the intravenous route, intrapleural administration of lipoplatin would both increase pleural tissue exposure and decrease systemic exposure to the drug.…”

Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations

“…The mean IC 50 values ranged from 19.7-36.8 μM (7.3-13.7 μg/ml) for carboplatin and 4.5-10.2 μM (1.4-3.1 μg/ml) for cisplatin in the LCL panels. In previous pharmacokinetic studies, plasma concentrations of platinum a few hours after administration ranged from 5-20 μg/ml in patients treated with carboplatin 37-39 and from 1-10 μg/ml in patients treated with cisplatin 38,40 .…”

Intrapleural polymeric films containing cisplatin for malignant pleural mesothelioma in a rat tumour model: a preliminary study☆

“…Cisplatinbased intrapleural chemotherapy became an increasingly accepted treatment option for patients with malignant pleural disease [18,19].…”

“…Lerza et al investigated the combination of cisplatin (60 mg m À2 ) and carboplatin (270 mg m À2 ) administered intrapleurally in patients with malignant pleural effusion [19]. Mean concentrations measured in the pleural cavity and plasma were 717 mg ml À1 and 5.1 mg ml À1 , respectively.…”